The total return over the past 12 months is +23.28% vs. +16.94% for the S&P 500. So far it's up +19.99% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +23.28% | +5.75% | (10.28%) | (6.79%) | (0.29%) | (9.88%) |
| Total Return CAGR | +23.28% | +5.75% | (10.28%) | (6.79%) | (0.29%) | (9.88%) |
| Revenue CAGR | (98.07%) | (67.47%) | (58.05%) | (32.27%) | (32.91%) | (17.83%) |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Celldex Therapeutics, Inc. (CLDX)
| Year | Start price | End price | CLDX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $27.16 | $32.59 | +19.99% | +14.51% | +5.48% |
| 2025 | $25.27 | $27.16 | +7.48% | +17.72% | (10.24%) |
| 2024 | $39.66 | $25.27 | (36.28%) | +24.89% | (61.17%) |
| 2023 | $44.57 | $39.66 | (11.02%) | +26.19% | (37.21%) |
| 2022 | $38.64 | $44.57 | +15.35% | (18.17%) | +33.52% |
| 2021 | $17.52 | $38.64 | +120.55% | +28.74% | +91.81% |
| 2020 | $2.23 | $17.52 | +685.65% | +18.37% | +667.28% |
| 2019 | $3.00 | $2.23 | (25.67%) | +31.22% | (56.89%) |
| 2018 | $42.60 | $3.00 | (92.96%) | (4.56%) | (88.40%) |
| 2017 | $53.10 | $42.60 | (19.77%) | +21.70% | (41.47%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
